Novel Combinations of Radiation and Immunotherapy

放射治疗和免疫治疗的新组合

• 批准号: 9779938
• 负责人: Jennifer Jones
• 金额: $ 12.16万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9779938
• 关键词: Biological; Cancer Biology; Cells; Cessation of life; Colorectal; Combination immunotherapy; Combined Modality Therapy; Development; Disease; Disseminated Malignant Neoplasm; Goals; Immune; Immunology; Immunotherapeutic agent; Immunotherapy; Malignant Neoplasms; Mediating; Metastatic Neoplasm to the Liver; Methods; Pancreas; Patients; Radiation; Radiation Oncologist; Radiation therapy; Radiosurgery; Research; Research Personnel; Training; Translating; Unresectable; austin; curative treatments; immunotherapy trials; irradiation; neoplasm immunotherapy; novel; post-doctoral training; programs; radiation effect; responders and non-responders; tumor; tumor microenvironment; vaccine trial

As a radiation oncologist with specialized training in radiosurgery and graduate and postdoctoral training in both cancer biology and general immunology, the ultimate goal of my research is to discover effective ways to combine immunotherapies (IT) with radiation therapy (RT), to promote systemic tumor control while achieving local tumor control. Toward this goal, I led the development of the NCI ROB extracranial Stereotactic Body Radiation Therapy (SBRT) program, and I am the primary ROB Associate Investigator working with Tim Greten and Austin Duffy (NCI/TGIB) on NCI's colorectal liver metastases (15-C-0021), and pancreas (15-C-0027) RT + IT studies. Ultimately, we plan to study EV subsets in responders and non-responders from immunotherapy trials (such as these RT + IT trials, NCI VB vaccine trials, and other tumor immunotherapy trials at NCI), to translate the EV subset signatures into biological information that could be used for personalized and adaptive treatments for our patients.

作为一名接受过放射外科专业培训，同时接受过癌症生物学和普通免疫学研究生和博士后培训的放射肿瘤学家，我研究的最终目标是发现将免疫治疗（IT）与放射治疗（RT）相结合的有效方法，在实现肿瘤局部控制的同时促进肿瘤的全身控制。为了实现这一目标，我领导了NCI ROB颅外立体定向放射治疗（SBRT）项目的开发，并且我是ROB的主要副研究员，与Tim Greten和Austin Duffy （NCI/TGIB）合作进行NCI结肠直肠肝转移（15-C-0021）和胰腺（15-C-0027） RT + IT研究。最终，我们计划研究免疫治疗试验（如RT + IT试验、NCI VB疫苗试验和NCI的其他肿瘤免疫治疗试验）中应答者和无应答者的EV亚群，将EV亚群特征转化为可用于患者个性化和适应性治疗的生物信息。